Complement C5 inhibition in patients with COVID-19 - a promising target?
Open Access
- 23 July 2020
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 105 (12) , 2847-2850
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Incidence of thrombotic complications in critically ill ICU patients with COVID-19Thrombosis Research, 2020
- Neutrophil extracellular traps in COVID-19JCI Insight, 2020
- Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five casesTranslational Research, 2020
- Complement as a target in COVID-19?Nature Reviews Immunology, 2020
- Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience2020
- WHO Declares COVID-19 a Pandemic2020
- The Emerging Role of Neutrophil Extracellular Traps in Respiratory DiseaseChest, 2019
- Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus PathogenesismBio, 2018
- Neutrophil Extracellular Traps in Pulmonary Diseases: Too Much of a Good Thing?Frontiers in Immunology, 2016
- Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumabBlood, 2015